Literature DB >> 20237928

Intravenous immunoglobulin therapy leading to dramatic improvement in a patient with systemic juvenile idiopathic arthritis and severe pericarditis resistant to steroid pulse therapy.

Tomomi Aizawa-Yashiro1, Eishin Oki, Kazushi Tsuruga, Tohru Nakahata, Etsuro Ito, Hiroshi Tanaka.   

Abstract

A 7-year-old Japanese boy with a 4-month history of systemic juvenile idiopathic arthritis (s-JIA) experienced disease flare with spiking fever, exanthema and arthralgia. He then developed progressive dyspnea due to severe pericarditis, and proinflammatory hypercytokinemia was suspected. Methylprednisolone pulse therapy was ineffective and echocardiography showed massive pericardial effusion had persisted. Alternatively, subsequent intravenous immunoglobulin (IVIG) therapy resulted in dramatic resolution of the pericardial effusion, and his general condition significantly improved within a few days. This case report may lend further support the use of IVIG for selected patients with s-JIA and severe pericarditis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20237928     DOI: 10.1007/s00296-010-1413-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  10 in total

1.  Intravenous immunoglobulin in treatment of cardiac tamponade in a patient with systemic lupus erythematosus.

Authors:  Tal Grenader; Linda Shavit
Journal:  Clin Rheumatol       Date:  2004-12       Impact factor: 2.980

Review 2.  New insights in systemic juvenile idiopathic arthritis--from pathophysiology to treatment.

Authors:  M Frosch; J Roth
Journal:  Rheumatology (Oxford)       Date:  2007-10-30       Impact factor: 7.580

3.  Clinical analysis of 570 cases with juvenile rheumatoid arthritis: results of a nationwide retrospective survey in Japan.

Authors:  S Fujikawa; M Okuni
Journal:  Acta Paediatr Jpn       Date:  1997-04

4.  Treatment of difficult cases of systemic-onset juvenile idiopathic arthritis with tacrolimus.

Authors:  Hiroshi Tanaka; Koji Tsugawa; Koichi Suzuki; Ei-shin Oki; Kazuhito Nonaka; Shigeru Kimura; Etsuro Ito
Journal:  Eur J Pediatr       Date:  2006-12-23       Impact factor: 3.183

5.  Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis.

Authors:  M Meissner; Y Sherer; Y Levy; H Chwalinska-Sadowska; P Langevitz; Y Shoenfeld
Journal:  Rheumatol Int       Date:  2000       Impact factor: 2.631

6.  A study of 20 SLE patients with intravenous immunoglobulin--clinical and serologic response.

Authors:  Y Levy; Y Sherer; A Ahmed; P Langevitz; J George; F Fabbrizzi; J Terryberry; M Meissner; M Lorber; J B Peter; Y Shoenfeld
Journal:  Lupus       Date:  1999       Impact factor: 2.911

7.  Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group.

Authors:  E D Silverman; G D Cawkwell; D J Lovell; R M Laxer; T J Lehman; M H Passo; L S Zemel; E H Giannini
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

8.  Efficacy of methylprednisolone pulse therapy in children with rheumatoid arthritis.

Authors:  Yahya Aghighi; Lida Attarod; Maryam Javanmard
Journal:  Clin Rheumatol       Date:  2008-07-05       Impact factor: 2.980

Review 9.  Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside.

Authors:  G Zandman-Goddard; M Blank; Y Shoenfeld
Journal:  Lupus       Date:  2009-09       Impact factor: 2.911

10.  Adult onset Still's disease and collapsing glomerulopathy: successful treatment with intravenous immunoglobulins and mycophenolate mofetil.

Authors:  A N Bennett; P Peterson; S Sangle; R Hangartner; I C Abbs; G R V Hughes; D P D'Cruz
Journal:  Rheumatology (Oxford)       Date:  2004-03-23       Impact factor: 7.580

  10 in total
  1 in total

Review 1.  Cardiovascular disease in patients with autoinflammatory syndromes.

Authors:  Rainer Hintenberger; Agnes Falkinger; Kathrin Danninger; Herwig Pieringer
Journal:  Rheumatol Int       Date:  2017-11-01       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.